Bayer AG (BAYZF) has four major operating segments namely Pharmaceutical, Consumer Health, Crop Science and Animal Health. In terms of stock price performance, it has been a rough year for the German pharmaceutical conglomerate. The stock price has nearly halved during the past 12 months.
Figure-1 (Source: Bayer)
Investor Takeaway:
In this analysis, I have compared BAYZF and selected competitors based on valuation and growth metrics. This comparison indicates that the stock is undervalued and likely to grow. A fundamental analysis of Q2 results also indicates business growth, thanks to the continuous R&D